HC Wainwright Has Positive Estimate for MBOT Q1 Earnings

Microbot Medical Inc. (NASDAQ:MBOT) – Investment analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Microbot Medical in a report issued on Thursday, April 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.40) EPS.

Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Microbot Medical Trading Up 11.8 %

Shares of MBOT opened at $2.55 on Monday. The company’s fifty day simple moving average is $1.68 and its 200 day simple moving average is $1.39. Microbot Medical has a 1-year low of $0.82 and a 1-year high of $3.38. The company has a market cap of $88.60 million, a price-to-earnings ratio of -3.19 and a beta of 1.40.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Microbot Medical stock. Geode Capital Management LLC increased its holdings in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 7.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 142,659 shares of the biotechnology company’s stock after purchasing an additional 10,442 shares during the period. Geode Capital Management LLC owned 0.70% of Microbot Medical worth $160,000 as of its most recent filing with the SEC. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.